Updated Jun 16, 7:54 PM · 60 sources analyzed
Key Takeaways
Lilly acquired non-opioid pain developer 4E and showed early myelofibrosis data, reinforcing its aggressive pipeline-building strategy beyond GLP-1.
Roche's tiragolumab Phase 3 NSCLC trial was terminated, deepening concerns about the viability of its anti-TIGIT program.
FDA staff flagged data shortcomings in Moderna's mRNA flu vaccine ahead of a Thursday advisory panel vote that could block U.S. approval.
🏆 Winner
Eli Lilly — closed a non-opioid pain acquisition and presented encouraging blood cancer data on the same day
📉 Loser
Roche — Phase 3 tiragolumab termination adds to a series of anti-TIGIT setbacks with no clear recovery path disclosed
🔭 Watch Next
The FDA advisory committee meeting on Moderna's mRNA influenza vaccine, scheduled for Thursday June 19, 2026, is the most immediate high-stakes event visible in today's sources.
Eli Lilly acquires non-opioid pain drugmaker 4E
Eli Lilly announced the acquisition of 4E, a company developing non-opioid pain therapies, adding to more than $18 billion in acquisitions Lilly has made over the past several years. Specific deal terms were not disclosed in the source. The move signals Lilly's intent to diversify beyond its GLP-1 franchise into the high-value non-opioid pain market, where competitive pressure is intensifying.
BioPharma Dive ↗Hoffmann-La Roche
Tiragolumab plus atezolizumab in Completely resected non-small cell lung cancer (NSCLC) after adjuvant chemotherapy
Specific figures not disclosed. The Phase 3 trial was terminated per ClinicalTrials.gov status update.
Why it matters
The termination adds to a pattern of setbacks for tiragolumab, the anti-TIGIT antibody, limiting Roche's ability to establish a competitive position in NSCLC adjuvant immunotherapy.
FDA approved Colorado's plan to import certain prescription drugs from Canada, making it the second U.S. state granted such authorization.
Expanded state-level drug importation from Canada increases pricing pressure on branded manufacturers selling into those markets and could accelerate similar approvals in other states.
STAT News ↗Moderna
mRNA influenza vaccine in Influenza prevention
Specific figures not disclosed. FDA staff highlighted shortcomings in the supporting data ahead of a Thursday advisory panel meeting. The FDA had previously refused to review this vaccine earlier in 2026.
Why it matters
A negative adcom recommendation Thursday could further delay or block Moderna's flu vaccine entry, reinforcing the dominance of established egg-based and recombinant flu vaccine manufacturers.
Edgewise Therapeutics
EDG-7500 in Hypertrophic cardiomyopathy (a condition where the heart muscle thickens, limiting pumping ability)
Specific figures not disclosed. The drug passed a key trial test; however, how meaningfully it differentiates from marketed competitors remains unclear.
Why it matters
Edgewise now competes directly with Bristol Myers Squibb's mavacamten and Cytokinetics' aficamten in the hypertrophic cardiomyopathy market, but differentiation data are not yet definitive.
Specific figures not disclosed. The drug passed a key trial test; however, how meaningfully it differentiates from marketed competitors remains unclear.
Why it matters
Edgewise now competes directly with Bristol Myers Squibb's mavacamten and Cytokinetics' aficamten in the hypertrophic cardiomyopathy market, but differentiation data are not yet definitive.
Specific figures not disclosed. Phase 1 results described as encouraging were presented at the European Hematology Association annual meeting in Stockholm.
Why it matters
A type II JAK2 inhibitor approach could offer a new mechanism in myelofibrosis, a market currently served by ruxolitinib and fedratinib, if later-phase results confirm the early signal.
Specific figures not disclosed. FDA staff highlighted shortcomings in the supporting data ahead of a Thursday advisory panel meeting. The FDA had previously refused to review this vaccine earlier in 2026.
Why it matters
A negative adcom recommendation Thursday could further delay or block Moderna's flu vaccine entry, reinforcing the dominance of established egg-based and recombinant flu vaccine manufacturers.
Specific figures not disclosed. The Phase 3 trial was terminated per ClinicalTrials.gov status update.
Why it matters
The termination adds to a pattern of setbacks for tiragolumab, the anti-TIGIT antibody, limiting Roche's ability to establish a competitive position in NSCLC adjuvant immunotherapy.
Specific figures not disclosed. The Phase 3 trial is active but no longer recruiting as of this ClinicalTrials.gov update.
Why it matters
Results from this study will determine whether the encorafenib-cetuximab combination can expand from second-line into first-line metastatic colorectal cancer, a significantly larger commercial opportunity.
FDA approved Colorado's plan to import certain prescription drugs from Canada, making it the second U.S. state granted such authorization.
Why it matters
Expanded state-level drug importation from Canada increases pricing pressure on branded manufacturers selling into those markets and could accelerate similar approvals in other states.
Moderna
FDA advisory committee meeting scheduled Thursday to review Moderna's mRNA influenza vaccine; FDA staff pre-meeting documents flagged data shortcomings.
Why it matters
If the advisory panel recommends against approval, Moderna's ability to diversify revenue beyond COVID-19 vaccines faces a material setback.
Eli Lilly
Eli Lilly acquires 4E, a non-opioid pain drug developer, extending a multi-year, $18 billion-plus acquisition spree.
Why it matters
The deal diversifies Lilly's pipeline into non-opioid pain, a therapeutically underserved area with significant commercial potential if candidates reach market.
Stereochemistry of lipid nanoparticles alters protein expression via internal lipid organization
A bioRxiv preprint reports that the three-dimensional arrangement (stereochemistry) of lipids within nanoparticles used to deliver mRNA directly affects how much protein those particles produce, through changes in internal lipid structure.
Why it matters
This finding suggests that controlling lipid stereochemistry during manufacturing could be a lever to tune the potency and safety of mRNA-based vaccines and gene therapies without changing the genetic payload.
iRhom2 adapter protein drives acute lung inflammation via ADAM17 pathway
A bioRxiv preprint shows that the non-enzyme scaffold protein iRhom2, which enables ADAM17 (an enzyme that releases inflammatory signaling molecules like TNF from cell surfaces), is a critical driver of acute lung inflammation in leukocytes.
Why it matters
Selective inhibition of iRhom2, rather than broad ADAM17 blockade, could offer a more targeted anti-inflammatory approach for conditions such as acute respiratory distress syndrome (ARDS) with a potentially better safety margin.
Novel bile salt analogs address both fatty liver disease and C. difficile infection in preclinical models
A bioRxiv preprint reports that synthetic bile salt analogs reduced lipid buildup in liver cells and showed activity against Clostridioides difficile (a drug-resistant gut bacterium) in laboratory models.
Why it matters
A single compound class targeting both metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD) and C. difficile infection could address a clinically co-occurring patient population with no current dual-indication treatment option.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Lilly acquired non-opioid pain drugmaker 4E, adding to more than $18 billion in acquisitions over recent years. Lilly also presented encouraging Phase 1 data for AJ1-11095, a type II JAK2 inhibitor for myelofibrosis acquired from Ajax Therapeutics, at the European Hematology Association meeting.
BioPharma Dive ↗BioPharma Dive noted that Edgewise's EDG-7500 Phase 2 heart drug results leave it unclear how different that drug is from Bristol Myers Squibb's mavacamten (Camzyos) for hypertrophic cardiomyopathy, positioning BMY as an incumbent being challenged.
BioPharma Dive ↗Roche's Phase 3 trial of tiragolumab plus atezolizumab in resected NSCLC was terminated, per ClinicalTrials.gov, marking another setback for the company's anti-TIGIT program.
ClinicalTrials.gov ↗Two Pfizer-sponsored trials updated on ClinicalTrials.gov today: a Phase 3 study of encorafenib plus cetuximab in first-line metastatic colorectal cancer is active but no longer recruiting, and a Phase 1/2 modified RNA influenza vaccine study is completed.
ClinicalTrials.gov ↗A completed Phase 3 ClinicalTrials.gov record for Novo Nordisk's once-weekly insulin icodec with the DoseGuide app versus daily insulins in type 2 diabetes was updated, indicating the study has concluded.
ClinicalTrials.gov ↗